We studied 102 children aged 1 month to 18 years in a randomized, double-blind trial designed to determine both the natural history of bacterial conjunctivitis and whether topical antibiotic therapy is beneficial. Affected eyes were treated four times a day for 7 days with drug (polymyxin-bacitracin ophthalmic ointment) or placebo. Eighty-four patients had proved bacterial conjunctivitis (Haemophilus influenzae 61, Streptococcus pneumoniae 22, both one); 66 of these received only topical therapy. By 3 to 5 days, 21 of 34 (62%) patients receiving topical antibiotic were clinically cured, whereas only nine of 32 (28%) patients given placebo were cured (P less than 0.02). By 8 to 10 days, 31 (91%) of the patients given antibiotic and 23 (72%) of the placebo group were cured (P = NS). The bacterial pathogen was eradicated by day 3 to 5 in 71% and by day 8 to 10 in 79% of patients given antibiotic, compared to 19% and 31% of the placebo group (P less than 0.001). Acute bacterial conjunctivitis is a self-limited disease, but topical antibiotic therapy with polymyxin-bacitracin shortens the duration of clinical disease and enhances eradication of the causative organism from the conjunctiva.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0022-3476(84)80566-1 | DOI Listing |
Arq Bras Oftalmol
January 2025
Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Purpose: This study aimed to report the use, efficacy, and safety of intracameral voriconazole as an adjuvant treatment for deep fungal keratitis.
Methods: This was a prospective case series of seven eyes with fungal keratitis with anterior chamber involvement or a corneal ulcer refractory to conventional topical treatment. In addition to topical treatment with 0.
Gynecol Oncol Rep
February 2025
Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL, United States.
Introduction: To report a series of patients who developed ocular surface disease related to tisotumab vedotin-tftv (TV), an antibody-drug conjugate (ADC) approved for the treatment of recurrent or metastatic cervical cancer.
Methods: This was a multicenter retrospective chart review study of patients who developed ocular surface disease related to TV between April 1st, 2022 to August 31st, 2023.
Results: Five patients were identified who developed ocular surface disease while on TV.
J Dent Sci
January 2025
Department of Oral and Maxillofacial Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Background/purpose: One of the causes of ventilator-associated pneumonia (VAP) is aspiration of oropharyngeal fluid containing pathogenic microorganisms into the lower respiratory tract. In this study, we aimed to investigate whether antibiotic ointment applied to the oral cavity can reduce the number of bacteria in the fluid on the cuff of a tracheal cannula.
Materials And Methods: Tetracycline ointment was applied intraorally once to a patient under endotracheal intubation by postoperative tracheostomy for oral cancer.
BMJ Case Rep
January 2025
Ophthalmology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.
Approximately 3% of individuals in road traffic accidents suffer ocular injuries. We present a case of a man in his late 80s who presented with bilateral corneal decompensation following airbag deployment during a road traffic accident. Ocular examination revealed multilevel ocular injury with severe bilateral corneal oedema.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Dermatology, Ninewells Hospital and Medical School Department of Dermatology, Dundee, UK.
A man in his early 40s presented with extensive skin lesions in the groin and genital regions. The lesions were erythematous and maculopapular but evolved into vesicles and pustules with surrounding cellulitis. He stated that he grips livestock between his legs for sheep shearing.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!